Myelofibrosis
Myelofibrosis
Advertisement
Katie KoskoMyelofibrosis | July 2, 2024
An exploratory analysis of the MOMENTUM trial evaluated how the JAK inhibitor impacted OS and LFS in these patients.
Read More
Cecilia BrownHematology & Blood Cancer | January 15, 2024
Researchers developed and piloted a novel phone-delivered positive psychology intervention called PATH.
Dustin SamplesHematology & Blood Cancer | October 17, 2023
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Cecilia BrownMyelofibrosis | October 17, 2023
Higher baseline quality of life independently predicted longer overall survival in patients with myelofibrosis.
Cecilia BrownMyelofibrosis | October 17, 2023
Pacritinib was found to be more effective than best available treatment at reducing spleen volume in myelofibrosis patients.
Cecilia BrownMyelofibrosis | October 17, 2023
Adding navitoclax to ruxolitinib treatment in patients with persistent or progressive myelofibrosis led to durable splee
Cecilia BrownMyelofibrosis | October 17, 2023
Myelofibrosis patients treated with fludarabine and busulfan along with TBI saw reduction in graft failure.
Patrick DalyMyelofibrosis | October 17, 2023
A trial examined weekly administration of LCL161 therapy in a large, high-risk, older study population with myelofibrosis ...
Ariel JonesMyelofibrosis | October 17, 2023
An analysis published in Annals of Hematology sought to add real-world context to findings from the phase II MYF2001 trial, ...
Ariel JonesMyelofibrosis | October 17, 2023
In a study published in Blood, investigators sought to define a new therapeutic target for the treatment of myelofibrosis ...
Ariel JonesMyelofibrosis | October 17, 2023
The JAK1/2 inhibitor ruxolitinib is a potent immunomodulator and effectively treats myeloproliferative disease such as ...
Ariel JonesMyelofibrosis | October 17, 2023
According to results from the ROMEI trial, patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib ...
Ariel JonesMyelofibrosis | October 17, 2023
Palbociclib, a drug approved to treat HR-positive and HER2-negative breast cancer, could lead to improvement in symptoms of ...
Ariel JonesMyelofibrosis | October 17, 2023
A phase II study of single-agent nivolumab in patients with myelofibrosis was terminated early, after failing to meet its ...
Ariel JonesMyelofibrosis | October 17, 2023
The JAK1/2 inhibitor ruxolitinib induced durable improvements in patients with primary and secondary myelofibrosis in the ...
Ariel JonesMyelofibrosis | October 17, 2023
A study published in the European Journal of Hematology evaluated the effects of various patient and clinical factors on ...
Ariel JonesMyelofibrosis | October 17, 2023
An analysis of data from the large, prospective, multinational, phase IIIb JUMP trial evaluated patient and disease ...
Ariel JonesMyelofibrosis | October 17, 2023
While ruxolitinib improves outcomes in patients with myelofibrosis (MF), some patients’ disease may have a suboptimal ...
Kerri FitzgeraldMyelofibrosis | November 16, 2023
Review outcomes in patients with myelofibrosis who choose to undergo HCT versus non-transplant therapies.
Kerri FitzgeraldMyelofibrosis | October 17, 2023
A study presented as part of the ASH 2020 Annual Meeting found that use of fedratinib for 24 or more weeks was well-tolerated ...
Advertisement
Advertisement
Advertisement